Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR1797238

· cohortSC

7136c23d-1ab2-5bcb-9eb0-baec34c5ee88

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortSC
subtype
cohortSC
age_years
62

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.340
  • WNT_BETA_CATENIN_SIGNALING+0.200
  • DNA_REPAIR+0.170
  • HEDGEHOG_SIGNALING+0.090
  • SPERMATOGENESIS+0.060
  • BILE_ACID_METABOLISM+0.020
  • KRAS_SIGNALING_DN+0.010
  • OXIDATIVE_PHOSPHORYLATION+0.010
  • NOTCH_SIGNALING-0.030
  • MYOGENESIS-0.050

Top 10 suppressed

  • ANGIOGENESIS-0.550
  • IL6_JAK_STAT3_SIGNALING-0.510
  • ALLOGRAFT_REJECTION-0.500
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
  • TNFA_SIGNALING_VIA_NFKB-0.480
  • INFLAMMATORY_RESPONSE-0.470
  • KRAS_SIGNALING_UP-0.460
  • INTERFERON_GAMMA_RESPONSE-0.430
  • G2M_CHECKPOINT-0.420
  • ANDROGEN_RESPONSE-0.410

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-0029
medullo-epn-umap@date-based
MedMedulloblastoma0.921
2SRR1797247
lung-landscapes@6
cohortSC0.917
3SRR1516072
bladder-landscape@3
0.916
4MDT-AP-1160
medullo-epn-umap@date-based
MedMedulloblastoma0.912
5TCGA-37-4129-01A-01R-1100-07
lung-landscapes@6
cohortSC0.909
6MDT-AP-1405
medullo-epn-umap@date-based
MedMedulloblastoma0.903
7MNG199
mng-umap@100
0.901
8MDT-AP-1345
medullo-epn-umap@date-based
MedMedulloblastoma0.900
9TCGA-E9-A245-01A-22R-A16F-07
breast-umap@18
B0.899
10MNG851
mng-umap@100
0.898

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 8 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.340Cobimetinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.200Inavolisib— uncovered
DNA_REPAIR0.170Idelalisib— uncovered
HEDGEHOG_SIGNALING0.090Inavolisib— uncovered
SPERMATOGENESIS0.060Inavolisib— uncovered
BILE_ACID_METABOLISM0.020Inavolisib— uncovered
KRAS_SIGNALING_DN0.010Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.010Remibrutinib— uncovered